Volume: 43 Issue: 3
Year: 2023, Page: 1059-1060, Doi: https://doi.org/10.51248/.v43i3.3192
An elderly female presented with abdominal pain, vomiting and easy fatigability. Her sensorium gradually declined and became comatose. She was on Methotrexate, folic acid and prednisolone for her rheumatoid arthritis. The neurological examination and neuroimaging did not contribute in making the diagnosis. It is challenging to diagnose a metabolic cause of coma. Once diagnosis is established, the management becomes easier. On detailed investigation, she was found to have severe hypercalcemia with corrected serum calcium level being 18.2 mg%. Serum vitamin D level was also high, 150 ng/ml. On probing for detailed history, it was revealed that she had been taking a weekly dose of 60,000 IU of vitamin D for nearly 5 years. In recent times, association of various diseases has been reported with vitamin D deficiency. Vitamin D supplementation seems justified in this patient considering her age and the fact that she had rheumatoid arthritis; she was also taking corticosteroid. The recommended dose of vitamin D has been 400–800 IU/day. However, it is often prescribed at a dose of 60,000 IU/week, and sometimes patients self-medicate. There are no guidelines available for prescribing vitamin D at such a strength. Though safety of vitamin D has been established, vitamin D toxicity can occur sporadically with serious consequences. This was managed with intravenous fluids and diuretics. The patient also required subcutaneous calcitonin and low dose of corticosteroid, in addition to a session of haemodialysis for her hypercalcemia. The patient’s sensorium gradually improved as her calcium level returned to normalcy.
Keywords: Hypercalcemia; hypervitaminosis D; coma
1. Kamath, D.K., Pai, M.V., Ummer, S., Kamath, S. Comparison of serum calcium, magnesium level and total antioxidant activity in pregnant women with and without gestational diabetes mellitus. Biomedicine. 2021 Sep 7;41(2):443-447.
2. Singh, K., Khubchandani, A., Singh, S. Alternations in serum vitamin D, calcium, phosphorus and lipid profile levels in newly diagnosed type 2 diabetic patients of North-West India. Biomedicine. 2021 Jul 7;41(2):189-193.
3. Tebben, P.J., Singh, R.J., Kumar, R. Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocrine reviews. 2016 Oct 1;37(5):521-547.
4. Marcinowska-Suchowierska, E., Kupisz-Urbanska, M., Lukaszkiewicz, J., Płudowski, P., Jones, G. Vitamin D toxicity–a clinical perspective. Frontiers in Endocrinology. 2018:550.
5. Basok, A.B., Rogachev, B., Haviv, Y.S., Vorobiov. M. Treatment of extreme hypercalcaemia: the role of haemodialysis. Case Reports. 2018 May 31; 2018: bcr-2017.
6. Gupta, A.K., Jamwal, V., Sakul, M.P., Malhotra, P. Hypervitaminosis D and systemic manifestations: a comprehensive review. JIMSA. 2014;27(4):236-237.
7. Ajlouni, K., Rosenfeld, P.S. Treatment of hypercalcemia. Drug Ther. 1974 Sep; 4:103-111.
8. Mehta, S., Nain, P., Agrawal, B.K., Singh, R.P., Kaur, J., Maity, S., et al., Effectiveness of Empagliflozin With Vitamin D Supplementation in Peripheral Neuropathy in Type 2 Diabetic Patients. Cureus. 2021 Dec 6;13(12): e20208.
9. Agrawal, B. K., Yadav, S. P., Kalia, S., Yadav, A., Kumar, A. Prevalence of vitamin D deficiency among COVID-19 patients: A cross-sectional study. International Journal of Health Sciences. 2022; 6(S3): 1655-1663.
Bimal K. Agrawal, Manu Mathew, Sahil Kalia, Aditi Tongar. Hypervitaminosis D induced hypercalcemia leading to coma: A case report. Biomedicine: 2023; 43(3): 1059-1060